Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 211

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 211
---
 Realized on Exercise (1) Number of Shares Acquired on Vesting Value Realized on Vesting (2) Christopher Anzalone 57,499 $ 1,024,000 95,087 $ 2,603,325 Kenneth Myszkowski — — 66,250 $ 2,212,813 Patrick O’Brien — — 63,750 $ 2,139,688 James Hamilton — — 52,500 $ 1,773,225 Javier San Martin —— —— 52,500 1,570,200 Tracie Oliver — — 17,625 $ 460,191 (1) Value is calculated as the price of our Common Stock upon exercise, less the exercise price, multiplied by the number of shares exercised. (2) Value is calculated as the price of our Common Stock upon vesting, multiplied by the number of shares vested. Termination Benefits — Potential Payments Upon Termination or Change in Control The Company has the following severance or change of control arrangements with its NEOs: Dr. Anzalone’s employment agreement with the Company provides that, if the Company terminates Dr. Anzalone’s employment without Cause or if Dr. Anzalone terminates his employment for Good Reason, on his date of termination, Dr. Anzalone will receive a one-time lump sum payment equal to the sum of: (i) one month of base salary and (ii) premiums for thirty (30) days of medical and dental benefits. To receive such payments Dr. Anzalone is required to execute a general release in favor of the Company. For purposes of Dr. Anzalone’s employment agreement: “Cause” means (i) the conviction (by trial or upon a plea of nolo contendere) of a felony or other crime involving moral turpitude or the commission of any other material act or omission involving dishonesty, disloyalty or fraud with respect to the Company or any of its subsidiaries or any of their customers or suppliers, (ii) reporting to work under the influence of alcohol or illegal drugs, the use of illegal drugs (whether or not at the workplace) or other repeated conduct causing the Company or any of its subsidiaries substantial public disgrace or disrepute or economic harm, (iii) the engaging of gross misconduct and the failure to cease such conduct and rectify any harm to the Company resulting therefrom within 30 days after written demand therefor by the Company identifying with reasonable particularity such conduct and harm, or (iv)